Spots Global Cancer Trial Database for First-in-human Study of S-588210 (S-488210+S-488211)
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: First-in-human Study of S-588210 (S-488210+S-488211)
Official Title: Open-label, Phase 1 Study of S-488210/S-488211 to Evaluate the Safety and Tolerability in Patients With Unresectable Recurrent and/or Metastatic Solid Tumor
Study ID: NCT04316689
Study Description
Brief Summary: The primary objective is to evaluate the safety and tolerability of S-588210 (S-488210+S-488211) in patients with unresectable recurrent and/or metastatic solid tumors.
Detailed Description:
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
University College London Clinical Research Facility, London, , United Kingdom
Contact Details
Name: Shionogi Clinical Trials Administrator Clinical Support Help Line
Affiliation: Shionogi
Role: STUDY_DIRECTOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
